Iga Glomerulonephritis (IGAN)

Categories: Immune diseases, Liver diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Iga Glomerulonephritis

MalaCards integrated aliases for Iga Glomerulonephritis:

Name: Iga Glomerulonephritis 12 15 17 70
Iga Nephropathy 12 73 20 36 15
Glomerulonephritis, Iga 20 44
Primary Immunoglobulin a Nephropathy 70
Iga Nephropathy, Susceptibility to 6
Berger's Iga or Igg Nephropathy 12
Segmental Glomerulonephritis 12
Focal Glomerulonephritis 12
Glomerulonephritis Focal 54
Primary Iga Nephropathy 12
Nephritis, Iga Type 20
Berger's Disease 20
Nephropathy Iga 54
Berger Disease 20
Igan 20


External Ids:

Disease Ontology 12 DOID:2986
KEGG 36 H01581
MeSH 44 D005922
NCIt 50 C34643
SNOMED-CT 67 236407003
UMLS 70 C0017661 C3161650

Summaries for Iga Glomerulonephritis

GARD : 20 IgA nephropathy is a kidney disorder that occurs when IgA (immunoglobulin A), a protein that helps the body fight infections, settles in the kidneys. IgA nephropathy can occur at any age, even in childhood. After many years, deposits of IgA may cause the kidneys to leak blood and sometimes protein in the urine. In the early stages, IgA nephropathy has no symptoms. The first sign of this condition may be blood in the urine. After 10 to 20 years, the kidneys may show signs of damage and 20-40% of adults develop end-stage kidney disease. In most instances, the cause of this condition is unknown; however, certain disorders have been linked with IgA nephropathy, such as cirrhosis of the liver, celiac disease, and HIV infection. Although IgA nephropathy usually occurs in a family with no other affected members, several cases of familial IgA nephropathy have been reported. Familial IgA nephropathy is suspected to run through families in an autosomal dominant manner and is linked to genetic material on the long arm of chromosome 6 (6q22-23). There is no cure for this condition. Treatment focuses on slowing the disease and preventing complications.

MalaCards based summary : Iga Glomerulonephritis, also known as iga nephropathy, is related to glomerulonephritis and focal segmental glomerulosclerosis. An important gene associated with Iga Glomerulonephritis is IGAN1 (IgA Nephropathy), and among its related pathways/superpathways are Staphylococcus aureus infection and Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and t cells, and related phenotypes are immune system and renal/urinary system

Disease Ontology : 12 A glomerulonephritis characterized by build up of IgA antibody in the glomerulus.

KEGG : 36 Primary IgA nephropathy is an immune-complex-mediated glomerulonephritis defined immunohistologically by the presence of glomerular IgA deposits accompanied by a variety of histopathologic lesions. It is known to be the most prevalent primary chronic glomerular disease worldwide. Because of the critical interaction between an intrinsic antigen (galactose-deficient IgA1) and circulating anti-glycan antibodies, IgA nephropathy can be considered an autoimmune disease. Since the features of IgA nephropathy identified by light microscopy are nonspecific, immunofluorescence or immunoperoxidase studies demonstrating a predominant deposition of IgA are essential to establish a definitive diagnosis of IgA nephropathy. Genetic factors undoubtedly influence the pathogenesis of IgA nephropathy. Genomewide association studies have identified common susceptibility loci in the absence of a priori mechanistic hypotheses.

Wikipedia : 73 IgA nephropathy (IgAN), also known as Berger's disease (/bɛərˈʒeɪ/) (and variations), or synpharyngitic... more...

Related Diseases for Iga Glomerulonephritis

Diseases related to Iga Glomerulonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 644)
# Related Disease Score Top Affiliating Genes
1 glomerulonephritis 31.5 SCGB1A1 NPHS2 NPHS1 MBL2 MASP1 CD79A
2 focal segmental glomerulosclerosis 31.3 NPHS2 NPHS1 CD2AP CCL2 ALB AGTR1
3 renal hypertension 31.2 REN NPHS1 ALB AGTR1 ACE
4 acute kidney tubular necrosis 31.1 REN NAGLU CCL2 ALB ACE
5 polycystic kidney disease 31.1 REN CD2AP CCL2 ALB AGTR1 ACE
6 mesangial proliferative glomerulonephritis 30.9 MBL2 CFHR2 CD79A CCL2
7 chlamydia 30.9 MBL2 CD79A CCL2
8 proteinuria, chronic benign 30.9 SERPINB7 REN NPHS2 NPHS1 NAGLU CD79A
9 eclampsia 30.9 REN ALB ACE
10 autosomal dominant polycystic kidney disease 30.9 REN CD79A CCL2 ALB AGTR1 ACE
11 membranoproliferative glomerulonephritis 30.8 NPHS1 CFHR2 CD79A ALB
12 vasculitis 30.8 MBL2 CD79A CD40LG CCL2
13 acute cystitis 30.8 REN CCL2 ALB ACE
14 pyelonephritis 30.8 NAGLU CCL2 ALB ACE
15 nephrotic syndrome 30.8 REN NPHS2 NPHS1 NAGLU CD79A CD2AP
16 spondyloarthropathy 1 30.8 FCAR CFHR2 CD40LG
17 nail-patella syndrome 30.7 NPHS2 NPHS1 CD2AP
18 otitis media 30.7 MBL2 CD79A ALB
19 portal hypertension 30.7 ALB AGTR1 ACE
20 vascular disease 30.7 REN CD40LG CCL2 ALB ACE
21 hemolytic uremic syndrome, atypical 1 30.7 MBL2 MASP1 CFHR2 ALB
22 glomerular disease 30.7 NAGLU CD79A CD2AP ALB ACE
23 acute proliferative glomerulonephritis 30.7 NPHS2 NPHS1 CCL2 ALB
24 nephrotic syndrome, type 2 30.6 NPHS2 NPHS1 CD2AP
25 malignant hypertension 30.6 REN CFHR2 AGTR1 ACE
26 hypertensive nephropathy 30.6 NAGLU ALB AGTR1 ACE
27 crescentic glomerulonephritis 30.6 SCGB1A1 NPHS2 CCL2
28 pulmonary edema 30.6 SCGB1A1 REN AGTR1 ACE
29 bacteriuria 30.6 CD79A CD40LG CCL2 ALB
30 silicosis 30.6 SCGB1A1 CCL2 ACE
31 c1q nephropathy 30.6 CD79A CD40LG
32 lung disease 30.6 SCGB1A1 MBL2 CCL2 ALB ACE
33 sleep apnea 30.6 REN CCL2 ALB ACE
34 respiratory papillomatosis, juvenile recurrent, congenital 30.6 MBL2 CD79A CD40LG
35 idiopathic nephrotic syndrome 30.5 NPHS2 ALB ACE
36 immunoglobulin g deficiency 30.5 MBL2 CD79A CD40LG
37 nephrosclerosis 30.5 NPHS2 NPHS1 CCL2 AGTR1 ACE
38 arteriolosclerosis 30.5 REN CD79A ALB
39 complement component 3 deficiency 30.5 MBL2 MASP1 CFHR2
40 end stage renal disease 30.5 REN NPHS2 NPHS1 CD2AP CCL2 ALB
41 acute poststreptococcal glomerulonephritis 30.5 CFHR2 CD79A ALB
42 microvascular complications of diabetes 5 30.5 ALB AGTR1 ACE
43 hypertension, essential 30.4 REN NPHS2 NPHS1 CD40LG CCL2 ALB
44 cardiac tamponade 30.4 REN ALB ACE
45 respiratory failure 30.4 SCGB1A1 REN CCL2 ALB ACE
46 aortic valve insufficiency 30.4 REN ALB ACE
47 pneumonia 30.4 SCGB1A1 MBL2 CD40LG CCL2 ALB ACE
48 hypertensive retinopathy 30.4 REN ALB AGTR1 ACE
49 apnea, obstructive sleep 30.4 REN ALB ACE
50 acute pyelonephritis 30.4 NAGLU ALB ACE

Graphical network of the top 20 diseases related to Iga Glomerulonephritis:

Diseases related to Iga Glomerulonephritis

Symptoms & Phenotypes for Iga Glomerulonephritis

MGI Mouse Phenotypes related to Iga Glomerulonephritis:

# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.73 ACE AGTR1 ALB C1GALT1 CCL2 CD2AP
2 renal/urinary system MP:0005367 9.44 ACE AGTR1 ALB C1GALT1 CD2AP CD40LG

Drugs & Therapeutics for Iga Glomerulonephritis

Drugs for Iga Glomerulonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
# Name Status Phase Clinical Trials Cas Number PubChem Id
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Hydroxychloroquine Approved Phase 4 118-42-3 3652
Enalaprilat Approved Phase 4 76420-72-9 6917719
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
Mycophenolic acid Approved Phase 4 24280-93-1 446541
Probucol Approved, Investigational Phase 4 23288-49-5 4912
Bortezomib Approved, Investigational Phase 4 179324-69-7 93860 387447
rituximab Approved Phase 4 174722-31-7 10201696
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Azathioprine Approved Phase 4 446-86-6 2265
Losartan Approved Phase 4 114798-26-4 3961
Ramipril Approved Phase 4 87333-19-5 5362129
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
Canagliflozin Approved Phase 4 842133-18-0
Empagliflozin Approved Phase 4 864070-44-0
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1 33036
31 interferons Phase 4
32 Interferon-alpha Phase 4
protease inhibitors Phase 4
34 HIV Protease Inhibitors Phase 4
35 Mitogens Phase 4
36 Cassava Phase 4
37 Antimetabolites Phase 4
38 Antimalarials Phase 4
39 Antiparasitic Agents Phase 4
40 Anti-Infective Agents Phase 4
41 Antiprotozoal Agents Phase 4
42 Antibiotics, Antitubercular Phase 4
43 Anti-Bacterial Agents Phase 4
44 Antitubercular Agents Phase 4
45 Omega 3 Fatty Acid Phase 4
46 Anticholesteremic Agents Phase 4
47 Lipid Regulating Agents Phase 4
48 Hypolipidemic Agents Phase 4
49 Vasoconstrictor Agents Phase 4
50 Nutrients Phase 4

Interventional clinical trials:

(show top 50) (show all 119)
# Name Status NCT ID Phase Drugs
1 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
2 A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy Unknown status NCT01184599 Phase 4 aliskiren
3 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
4 Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
5 A Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Unknown status NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
6 A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
7 Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease Completed NCT02351752 Phase 4 Hydroxychloroquine Sulfate
8 Long-term Treatment by Inhibitors of Angiotensin II at Low Doses in Non-nephrotic Proteinuric Patients With Pauciimmune and IgA Mesangioproliferative Glomerulonephritis Completed NCT01115426 Phase 4 Ramipril or losartan
9 The Safety and Short-Term Efficacy of Calcitriol in the Treatment of Immunoglobulin A Nephropathy Completed NCT00319761 Phase 4 Calcitriol
10 A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy Completed NCT00498368 Phase 4 Intravenous Rituximab;ACE/ARB
11 Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy Completed NCT00367562 Phase 4 ENALAPRIL VALSARTAN METHYLPREDNISONE
12 A Prospective, Randomized, Open Label, Case-Controlled Study on the Efficacy of Mycophenolate Mofetil for IgA Nephropathy Patients With Heavy Proteinuria Despite Angiotensin Blockade Completed NCT00863252 Phase 4 mycophenolate mofetil;angiotensin blockade
13 Corticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial. Completed NCT00755859 Phase 4 steroids plus azathioprine;steroids
14 Aliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot Study Completed NCT00922311 Phase 4 Aliskiren
15 A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Completed NCT00426348 Phase 4 Valsartan;Probucol;Placebo
16 Velcade Therapy for Severe IgA Nephropathy Completed NCT01103778 Phase 4 Bortezomib (Velcade®)
17 A Multicentre, Randomized, Controlled Study of Rituximab in Treatment of Primary IgA Nephropathy Recruiting NCT04525729 Phase 4 Rituximab;RAS 2410
18 A Randomized, Controlled Trial to Evaluate Leflunomide Plus Low Dose Corticosteroid Therapy in Progressive IgA Nephropathy With Renal Insufficiency Recruiting NCT04020328 Phase 4 Leflunomide 20 mg+prednisone 0.5mg/kg/d
19 An Extended Follow-up of the Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced Stage IgA Nephropathy Active, not recruiting NCT03218852 Phase 4 prednisone and cyclophosphamide;prednisone alone
20 Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. Not yet recruiting NCT04662723 Phase 4 Corticosteroid;Renin-angiotensin sytem blockers;Sodium-glucose cotransporter 2 inhibitor
21 Effect of Immunosuppression in IgA Nephropathy Not yet recruiting NCT03468972 Phase 4 Immunosuppressive treatment
22 Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment Terminated NCT02523768 Phase 4 ATG-F;Simulect
23 Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
24 Impact of Acthar on Proteinuria and Disease Progression in IgA Nephropathy Patients With Nephrotic Range Proteinuria Withdrawn NCT02382523 Phase 4 Acthar 80 unit injection
25 Phase 3 Study of Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f Unknown status NCT02187900 Phase 3 Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH);Mycophenolate mofetil (MMF)
26 Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy -- A Prospective, Randomized, Controlled, Multi-Center Clinical Trial Unknown status NCT02662283 Phase 2, Phase 3 Prednisolone;Reh-acteoside
27 Steroids and Azathioprine in Early and Advanced IgA Nephropathy: Amendments to a Prospective Randomised Multicenter Trial Completed NCT01392833 Phase 3 methylprednisolone;azathioprine;prednisone
28 A Prospective, Multicenter, Randomized Controlled Trial of Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN) Completed NCT00657059 Phase 3 irbesartan;methylprednisolone (MP) or prednisone (pred);mycophenolate mofetil (MMF)
29 An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression Completed NCT02282930 Phase 3 ACTH (Acthar) Gel
30 Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial Completed NCT01225445 Phase 3 Ramipril
31 Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy Completed NCT00554502 Phase 3 supportive therapy with: ACE-inhibitor / ARB / Statin;supportive and immunosuppressive therapy
32 Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA Nephropathy Completed NCT00549692 Phase 3 Omega-3 fatty acid ethylester90
33 The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study Completed NCT00870493 Phase 3 Aliskiren;Placebo
34 A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Completed NCT02062684 Phase 2, Phase 3 Blisibimod;Placebo
35 A Prospective Study Evaluating the Efficacy and Safety of Losartan in Children With Immunoglobulin A Nephropathy Completed NCT02232776 Phase 3 Losartan
36 A Randomized, Double-blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd) Recruiting NCT03643965 Phase 3 Nefecon;Placebo oral capsule
37 A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients Recruiting NCT04578834 Phase 3 Placebo;LNP023
38 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN) Recruiting NCT03608033 Phase 3
39 Treatment of IgA Nephropathy According to Renal Lesions Recruiting NCT03188887 Phase 3 corticotherapy;Renin Angiotensin system (RAS) blockade
40 A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function Recruiting NCT04573478 Phase 3 Atrasentan;Placebo
41 Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of End-stage Renal Disease (TCM-WINE) Recruiting NCT03418779 Phase 2, Phase 3 The Yi-Qi-Qing-Jie herbal compound;Immunosuppressants
42 A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy Recruiting NCT03762850 Phase 3 sparsentan;irbesartan
43 Randomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis of IgA NEphropathy (RESCUE Study) Enrolling by invitation NCT02647255 Phase 2, Phase 3 Methylprednisolone pulse
44 An Open-Label Extension (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301 Not yet recruiting NCT04541043 Phase 3 Nefecon
45 A Multicenter Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label LNP023 in Patients With Primary IgA Nephropathy Who Have Completed Study CLNP023X2203 or CLNP023A2301 Not yet recruiting NCT04557462 Phase 3 LNP023
46 A Randomized, Double Blinded, Placebo-controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Losartan in Early Immunoglobulin A Nephropathy (IgAN) Patients Not yet recruiting NCT03357653 Phase 3 Losartan group;Placebo group
47 A Randomized Controlled Trial of Mycophenolate Mofetil in Patients With IgA Nephropathy Terminated NCT00318474 Phase 3 Mycophenolate Mofetil (MMF);MMF Placebo;ACEi;FOS
48 Paricalcitol for the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study Withdrawn NCT00599963 Phase 3 paricalcitol
49 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Withdrawn NCT02052219 Phase 3 Blisibimod;Placebo
50 Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial. Unknown status NCT02160132 Phase 2 Methylprednisolone(intravenously in the 1st-2nd-3rd month );Methylprednisolone(intravenously in the 1st-3rd-5th month)

Search NIH Clinical Center for Iga Glomerulonephritis

Cochrane evidence based reviews: glomerulonephritis, iga

Genetic Tests for Iga Glomerulonephritis

Anatomical Context for Iga Glomerulonephritis

MalaCards organs/tissues related to Iga Glomerulonephritis:

Kidney, Liver, T Cells, Endothelial, Bone, Bone Marrow, Monocytes

Publications for Iga Glomerulonephritis

Articles related to Iga Glomerulonephritis:

(show top 50) (show all 7060)
# Title Authors PMID Year
Variation in IGHMBP2 is not associated with IgA nephropathy in independent studies of UK Caucasian and Chinese Han patients. 54 61
20031928 2010
Corticosteroids plus ACE inhibitors for IgA nephropathy. 54 61
20157171 2010
[IgA1 aberrant glycosylation in the pathogenesis of IgA nephropathy: an overivew]. 54 61
20337060 2010
Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series. 61 54
20042261 2010
alpha- and beta-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy. 54 61
19838659 2010
An emerging role of deubiquitinating enzyme cylindromatosis (CYLD) in the tubulointerstitial inflammation of IgA nephropathy. 61 54
19800320 2009
Primary IgA nephropathy is more severe in TGF-beta1 high secretor patients. 54 61
19967654 2009
Genetic variation in the transforming growth factor-beta1 gene is associated with susceptibility to IgA nephropathy. 54 61
19258388 2009
[Expression of MCP-1 in renal tissues of patients with IgA nephropathy]. 61 54
19893256 2009
[Clinical and pathological analysis of 217 patients with IgA nephropathy from Hainan Province]. 54 61
19620078 2009
Mesangial medium with IgA1 from IgA nephropathy inhibits nephrin expression in mouse podocytes. 54 61
19397686 2009
TRAC variants associate with IgA nephropathy. 61 54
19470682 2009
Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy. 61 54
19557716 2009
Tonsillectomy with methylprednisolone pulse therapy as rescue treatment for steroid-resistant IgA nephropathy in children. 54 61
19398868 2009
Is complement factor H a susceptibility factor for IgA nephropathy? 54 61
19162324 2009
[Association of NPHS1 gene polymorphism with IgA nephropathy]. 54 61
19671286 2009
Effect of aggregated immunoglobulin A1 from immunoglobulin A nephropathy patients on nephrin expression in podocytes. 54 61
19019169 2009
Mesangial C4d deposition: a new prognostic factor in IgA nephropathy. 61 54
18842673 2009
Activated intrarenal reactive oxygen species and renin angiotensin system in IgA nephropathy. 54 61
19417726 2009
Antiproteinuric effect of olmesartan in patients with IgA nephropathy. 54 61
19384840 2009
The heme oxygenase-1 genotype is a risk factor to renal impairment of IgA nephropathy at diagnosis, which is a strong predictor of mortality. 54 61
19194559 2009
Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. 54 61
18930568 2009
CD19+CD5+ B cells in primary IgA nephropathy. 54 61
18650480 2008
The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients. 54 61
19037561 2008
BMP-7 protects mesangial cells from injury by polymeric IgA. 54 61
18496506 2008
Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. 61 54
18971549 2008
[Correlation of TFRC polymorphism with the susceptibility and clinicopathologic phenotypes of IgA nephropathy]. 54 61
18677382 2008
Megsin 2093T-2180C haplotype at the 3' untranslated region is associated with poor renal survival in Korean IgA nephropathy patients. 54 61
18793525 2008
alpha1-antitrypsin (A1AT) deficiency presenting with IgA nephropathy and nephrotic syndrome: is renal involvement caused by A1AT deposition? 54 61
18793532 2008
IgA nephropathy: lessons from an animal model, the ddY mouse. 61 54
18651534 2008
Improved renal survival in Japanese children with IgA nephropathy. 61 54
18224344 2008
[Expression and clinical implication of platelet-derived growth factor-D and platelet-derived growth factor-beta in childhood IgA nephropathy]. 61 54
18471357 2008
Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol. 54 61
18587715 2008
Mutations in FN1 cause glomerulopathy with fibronectin deposits. 54 61
18268355 2008
Mutations in the familial Mediterranean fever gene of patients with IgA nephropathy and other forms of glomerulonephritis. 54 61
18177471 2008
Tubulointerstitial heparan sulfate proteoglycan changes in human renal diseases correlate with leukocyte influx and proteinuria. 61 54
18032547 2008
Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. 61 54
18925530 2008
TGF-beta1 and CTGF mRNAs are correlated with urinary protein level in IgA nephropathy. 61 54
18264937 2008
Mast cells, TGF-beta1 and alpha-SMA expression in IgA nephropathy. 54 61
18334740 2008
Influence of cytokine gene polymorphisms on IgA nephropathy. 61 54
18300111 2008
The influence of two megsin polymorphisms on the progression of IgA nephropathy. 61 54
18498720 2008
Lack of association between NPHS2 gene polymorphisms and sporadic IgA nephropathy. 54 61
17635752 2007
Plasma exchange combined with immunosuppressive treatment in a child with rapidly progressive IgA nephropathy. 54 61
17285293 2007
Absence of increased alpha1-microglobulin in IgA nephropathy proteinuria. 54 61
17242005 2007
Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. 61 54
17228361 2007
Association between the clara cell secretory protein (CC16) G38A polymorphism and the progression of IgA nephropathy. 61 54
17338426 2007
Transferrin receptor engagement by polymeric IgA1 induces receptor expression and mesangial cell proliferation: role in IgA nephropathy. 54 61
17495453 2007
Impact of ACE gene polymorphisms on the progression of IgA nephropathy in India. 61 54
17654331 2007
Angiotensin antagonists and fish oil for treating IgA nephropathy. 54 61
17495434 2007
Pathogenesis of IgA nephropathy. 54 61
17495430 2007

Variations for Iga Glomerulonephritis

ClinVar genetic disease variations for Iga Glomerulonephritis:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SELE NM_000450.2(SELE):c.1402C>T (p.His468Tyr) SNV Uncertain significance 16667 rs5368 GRCh37: 1:169696946-169696946
GRCh38: 1:169727805-169727805

Expression for Iga Glomerulonephritis

Search GEO for disease gene expression data for Iga Glomerulonephritis.

Pathways for Iga Glomerulonephritis

GO Terms for Iga Glomerulonephritis

Cellular components related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 SERPINB7 SCGB1A1 REN MBL2 MASP1 CD40LG
2 extracellular region GO:0005576 9.32 SCGB1A1 REN MBL2 MASP1 FCAR CFHR2
3 slit diaphragm GO:0036057 9.16 NPHS2 NPHS1

Biological processes related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 amyloid-beta metabolic process GO:0050435 9.4 REN ACE
2 angiotensin maturation GO:0002003 9.37 REN ACE
3 neutrophil mediated immunity GO:0002446 9.32 FCAR ACE
4 complement activation, lectin pathway GO:0001867 9.26 MBL2 MASP1
5 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.16 AGTR1 ACE
6 renin-angiotensin regulation of aldosterone production GO:0002018 8.96 REN AGTR1
7 kidney development GO:0001822 8.92 REN C1GALT1 AGTR1 ACE

Molecular functions related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 bradykinin receptor binding GO:0031711 8.62 AGTR1 ACE

Sources for Iga Glomerulonephritis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....